Osteochondritis Dissecans Clinical Trial
Official title:
Evaluation of the Agili-C Bi-phasic Implant Performances in the Repair of Cartilage and Osteochondral Defects
NCT number | NCT01471236 |
Other study ID # | CLN0002 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2011 |
Est. completion date | November 19, 2018 |
Verified date | February 2020 |
Source | Cartiheal (2009) Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the performance of the Agili-C implants. The study hypothesis is that Agili-C implants are effective in the treatment of focal cartilage and cartilage-bone joint surface defects.
Status | Completed |
Enrollment | 65 |
Est. completion date | November 19, 2018 |
Est. primary completion date | November 19, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria 1. 18 to 55 years 2. Symptomatic, single, focal, full or near full-thickness (ICRS cartilage defect description grades 3 and 4) chondral or osteochondral isolated lesion of the femoral condyle, trochlea or the tibial plateau - Defect area is less than 2 cm² after debridement. The defect is completely surrounded on all sides by healthy cartilage. - Osteochondral defect ICRS Cartilage defect description type 1, 2, 3, 4A. Maximal defect depth should be up to 3 millimeters. 3. Primary or secondary articular cartilage repair. 4. Knee is stable or can be stabilized as a concomitant procedure. 5. Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely schedule clinical and radiographic visits. 6. Signed informed consent. 7. Any misalignments should be fully corrected at the end of the operative procedure. Exclusion Criteria 1. Uncorrected axial misalignments >5° that cannot be corrected. 2. Patellar cartilage defects or pathology. 3. Meniscal resection of more than 50%, either in a previous procedure or concomitant with articular cartilage repair. 4. Any tumor of the ipsilateral knee, any concurrent malignant tumor or any metastatic tumor in the past or in the present. 5. Active acute or chronic infection of the treated knee. 6. Inflammatory arthropathy or crystal-deposition arthropathy. 7. Systemic cartilage and/or bone disorder; This implants integration is dependent on surrounding live bleeding bone; therefore it must not be implanted within sequestrated or necrotic bone. 8. Bony defect depth over 3 millimeters. 9. Body mass index >35. 10. Asymptomatic articular cartilage defects. 11. Bipolar articular cartilage defects. 12. Osteoarthritis of the operated knee. 13. Oral medications such as systemic corticosteroid therapy taken less than one year prior to surgery or chemotherapy. - Previous operative treatment of Arthroscopic marrow stimulation technique or cell therapy operated within the last 6 months - Any previous operation of cartilage treatment within the last 6 months 14. Patients who are sensitive to materials containing calcium carbonate or hyaluronate 15. Pregnant women, women who plan to become pregnant and breastfeeding women. 16. Evidence of any significant systemic disease (such as but not limited to HIV infection, hepatitis infection or HTLV infection), known coagulopathies, severe vascular or neurological disease or acute injury that might compromise the patient's welfare. 17. Substance abuse or alcohol abuse. 18. Participation in another clinical trials in parallel to this study. 19. Type I diabetes. 20. Unable to undergo MRI or X-ray. 21. Any reasons making the patient a poor candidate in the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
Croatia | Clinical Hospital ''Sveti Duh'' | Zagreb | |
Czechia | Fakultní nemocnice Brno | Brno | |
Hungary | Uzsoki Street Hospital | Budapest | |
Italy | Rizzoli Orthopaedic Institute | Bologna | |
Poland | Avimed Hospital | Katowice | |
Romania | County Hospital of Timisoara, | Timisoara | |
Serbia | Institut Za Ortopediju "Banjica" | Belgrade | |
Serbia | Clinical center of Vojvodina | Novi Sad | |
Slovenia | University Medical Centre, Ljubljana | Ljubljana |
Lead Sponsor | Collaborator |
---|---|
Cartiheal (2009) Ltd |
Croatia, Czechia, Hungary, Italy, Poland, Romania, Serbia, Slovenia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | number of SAE | Complications and adverse events, device-related or not, will be evaluated over the course of the clinical trial, including subsequent surgical interventions | 24 months | |
Primary | improvement in KOOS pain subscales | The primary efficacy endpoint for this trial will be the change from baseline up to 24 months visit in pain score as measured by the KOOS pain subscale | 24 months | |
Secondary | KOOS total score | Change from baseline to 3, 6, 9, 12, 18 and 24 months visits as measured by the KOOS total score and subscales.
Change from baseline to 18 and 24 months visit in IKDC current health assessment. Change from baseline to 3, 6, 12, 18 and 24 months visit in Lysholm with Tegner knee score. Change from baseline to 3, 6, 12 , 18 and 24 months visit in IKDC knee examination form 2000 Change from baseline to 3, 6, 12 , 18 and 24 months visit in IKDC subjective knee evaluation Change in MOCART scoring as measured at 3, 6, 12 , 18 and 24 months visit |
24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01458782 -
ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee
|
N/A | |
Active, not recruiting |
NCT02771496 -
Osteochondritis Dissecans of Knee Prospective Cohort
|
||
Completed |
NCT02397278 -
Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee
|
N/A | |
Active, not recruiting |
NCT01347892 -
DeNovo NT Ankle LDC Study
|
N/A | |
Recruiting |
NCT01409447 -
Repair of Articular Osteochondral Defect
|
N/A | |
Active, not recruiting |
NCT03656185 -
Elbow Arthroscopy Data Analysis
|
||
Not yet recruiting |
NCT06462040 -
Evaluation of Clinical and Radiological Outcomes in Patients Undergoing Fixation of Osteochondral Fragments With Reasorbable Screws in the Knee Joint
|
||
Enrolling by invitation |
NCT01455987 -
Osteochondritis Dissecans of the Knee
|
N/A | |
Recruiting |
NCT01159899 -
Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee
|
Phase 0 | |
Terminated |
NCT00881023 -
Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration
|
N/A | |
Recruiting |
NCT04364334 -
Knee Registry (Knieregister)
|
||
Recruiting |
NCT01498029 -
Knee Articular Cartilage Repair: Cartilage Autograft Implantation System Versus Conventional Microfracture
|
Phase 3 | |
Completed |
NCT03452098 -
Post-Operative Rehabilitation of Knee Osteochondral Defect: A Case Series
|
||
Completed |
NCT04297449 -
Prospective 2-year Data Collection of the First 10 Patients After Ankle Spacer Implantation
|
||
Suspended |
NCT02664337 -
Conjoint Analysis of Patient Preferences in Joint Interventions
|
N/A | |
Active, not recruiting |
NCT01329445 -
DeNovo NT Longitudinal Data Collection (LDC) Knee Study
|
N/A | |
Completed |
NCT02993510 -
A Randomized Controlled Trial Comparing Chondro-Gide® to Microfracture Alone for Treatment of Knee Cartilage Defects.
|
Phase 3 | |
Recruiting |
NCT01694823 -
Safety and Efficacy Study of Cells Sheet-Autologous Chondrocyte Implantation to Treat Articular Cartilage Defects
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01283737 -
Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD)
|
Phase 4 |